Oxford Science Enterprises

What Oxford Science Enterprises does

Oxford Science Enterprises (OSE) is an independent investment company and venture builder founded in 2015 in Oxford, United Kingdom, in formal partnership with the University of Oxford. The firm operates a "Find-Fund-Build" model that identifies breakthrough research from Oxford, Harwell, and Culham, provides long-duration patient capital, and co-creates spinout companies alongside academic founders and an in-house Entrepreneurs-in-Residence programme. Its 60+ person team is organized across three sector verticals — Deep Tech, Life Sciences, and HealthTech — and supports portfolio companies with operational assistance, board-level governance, recruiting, and access to a global co-investor network.

OSE's portfolio spans 50+ flagship companies including quantum computing firms (Oxford Ionics, Oxford Quantum Circuits, Quantum Motion), biotechs (Dark Blue Therapeutics, Beacon Therapeutics, Alethio Therapeutics, Scripta Therapeutics), HealthTech platforms (Ultromics, Kneu Health/Neu Health), agricultural technology (Wild Bioscience), AI chip developers (Fractile), and aerospace/defence ventures (Applied Atomics). The firm has deployed £3 billion+ alongside 300+ co-investors, holds £1.3 billion in net asset value, and has raised over £850 million from global institutional investors including sovereign wealth funds, family offices, pension funds, and asset managers.

The business model is structured as a venture capital platform: OSE generates revenue through management fees on its £850M+ of raised capital and £1.3B NAV, plus carried interest crystallized on successful portfolio exits. The firm is FCA-authorized through its wholly-owned subsidiary OSE Manager Limited, operates as a public limited company (Oxford Science Enterprises plc), and facilitates secondary trading of its shares via the London Stock Exchange's PISCES platform. Notable recent exits include Oxford Ionics' $1.075 billion acquisition by IonQ (June 2025) and Dark Blue Therapeutics' acquisition by Amgen for up to $840 million (January 2026), alongside active partnerships with The Crown Estate, Pioneer Group, Ellison Institute of Technology, Cedars-Sinai, and Tokyu Land to expand geographic reach and physical infrastructure.

Name

Oxford Science Enterprises

Legal name

Oxford Science Enterprises plc

Website

https://oxfordscienceenterprises.com/

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Oxford Science Enterprises is an independent venture capital and venture-building firm founded in 2015 in partnership with the University of Oxford. It finds, funds, and builds companies from Oxford science across Deep Tech, Life Sciences, and HealthTech, with 50+ portfolio companies and £1.3B NAV.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Emerging Manager / Seeding Platforms (Multi-Manager) (FSANAGAF)

akta.pro secondary industry

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

Keywords

• Venture capital services
• Venture building
• University spinout investment
• Life sciences venture
• Deep tech investing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Investment Management: OSE operates as an independent investment company that generates returns through capital appreciation of its portfolio companies. Revenue is derived from management fees on funds under management and carried interest on successful exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Oxford Science Enterprises is an independent investment company and venture builder that finds, funds, and builds companies based on University of Oxford science across Deep Tech, Life Sciences, and HealthTech. It deploys patient capital across pre-seed to growth stages, co-creates ventures with researchers and Entrepreneurs-in-Residence, and provides operational support including strategy, recruitment, business development, and access to lab/startup space. The firm partners with global specialist investors to co-invest and scale Oxford spinouts from lab breakthrough to commercial company.

Product overview

Oxford Science Enterprises is an independent investment company and venture builder powered by a unique partnership with the University of Oxford. Rather than offering a single unified product, the company operates a venture-building engine that systematically creates and scales spinout companies across three sectors: Deep Tech, Life Sciences, and HealthTech. Their model involves identifying bold ideas from Oxford researchers, funding them with patient capital, and building companies ready to change the world. The portfolio includes quantum computing companies (Oxford Ionics, Oxford Quantum Circuits), biotech firms (Dark Blue Therapeutics, Beacon Therapeutics, Alethio Therapeutics), agricultural technology (Wild Bioscience), medical AI diagnostics (Ultromics, Kneu Health), and numerous other specialized ventures. As of 2026, the firm has built 50+ flagship companies, attracted 300+ co-investors, and manages £1.3 billion in net asset value.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Building and Investment Services An integrated venture capital and venture-building service that finds, funds, and builds transformational companies from University of Oxford science across Deep Tech, Life Sciences, and HealthTech. Delivered to (a) Oxford researchers and innovators seeking to commercialise breakthroughs, and (b) global investors seeking exposure to Oxford spinouts through co-investment and OSE plc equity. Includes pre-seed to growth-stage equity investment, patient capital, Entrepreneurs-in-Residence, recruitment, strategy, business development, and 55,000+ sq ft of laboratory and startup space.

Quantifiable outcome

• Created 50+ flagship companies from Oxford science since 2015
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• The Crown EstatecoreStrategic or Co-development Partner · 21 March 2026Partnership to convert former Debenhams building at 1-12 Magdalen Street in Oxford into a 100,000 sq ft laboratory and innovation hub for life sciences, technology and research businesses. The £125m development is scheduled for 2027-2029.
• Pioneer GroupcoreStrategic or Co-development Partner · 21 March 2026Science and innovation developer partnering with OSE and The Crown Estate to develop the 100,000 sq ft laboratory and innovation hub in Oxford.
• Archangel Lightworks (Omantel partnership facilitated by OSE)minorStrategic or Co-development Partner · 18 December 2025OSE facilitated partnership between Archangel Lightworks and Omantel to introduce laser-optic satellite ground station communication technologies in Oman, including proof-of-concept trials and joint R&D.
• UK Government / Chancellor Reeves Gulf MissionminorOthers · 27 October 2025OSE participated in UK Chancellor's Gulf trade mission alongside Darktrace and Oxford Nanopore Technologies to promote UK investment opportunities.
• Tokyu LandminorStrategic or Co-development Partner · 7 August 2025Partnership to connect Oxford spinouts with Japan's innovation ecosystem, helping portfolio companies access the Japanese market and potential partners/investors.
• Cedars-SinaicoreStrategic or Co-development Partner · 29 January 2025Strategic partnership and co-investment in neurology care company Kneu Health (now Neu Health), with Cedars-Sinai adopting the platform and investing to accelerate U.S. market entry.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cambridge Innovation Capital: CIC is the closest analogue to OSE: a Cambridge University-partnered venture builder that invests in deep tech and life sciences spinouts from a single elite research university. The model, university anchor, sector mix, and UK base make it the most directly comparable peer.
• Apollo Therapeutics: A venture builder partnering with multiple UK universities (Cambridge, UCL, Imperial) to translate academic research into biotech companies. Comparable in university-partnered venture building and life-sciences focus, with a multi-institution twist that contrasts with OSE's single-university anchor.
• IP Group: UK-listed IP commercialization firm that partners with multiple universities to form and back spinouts across life sciences, deep tech, and cleantech. Closely comparable in commercialization model and sector mix, though it works with a portfolio of universities rather than a single anchor.

Broad incumbents

• Oxford University Innovation: Oxford's official technology transfer office and OSE's primary partner. Comparable in mission (commercializing Oxford IP) and customer base, but operates as the university's in-house tech-transfer function rather than a venture-building investor, making it more of an upstream enabler than a direct competitor.
• Flagship Pioneering: US-based venture creation firm that originates and builds biotech and life-sciences companies. Comparable in 'venture builder' DNA and life-sciences focus, but operates at much larger scale, is private, and does not anchor to a single university.
• Wellcome Leap: US-based program of the Wellcome Trust funding breakthrough life-sciences and health research. Comparable in life-sciences/health focus and willingness to back early-stage, capital-intensive science, but operates as a philanthropic program rather than a return-driven VC.
• SVB Capital / Silicon Valley Bank Ventures: Long-standing US investor in university spinouts and life-sciences/deep-tech companies. Comparable in supporting deep tech and life-sciences venture creation, with a more diversified LP-funded model rather than a single-university anchor.
• Mubadala Capital Ventures: Sovereign-backed investor with global venture activity including deep tech and life sciences. Comparable in deploying very large pools of patient capital into long-horizon science, though diversified across sectors and geographies rather than university-anchored.

Emerging players

• The Engine (MIT): MIT-affiliated venture fund focused on 'tough tech' (deep tech, advanced materials, energy, biotech). Comparable as a university-anchored deep-tech investor and venture builder, though smaller in scale and US-based rather than UK-based.

Regional players

• Parkwalk Advisors: UK-based investor focused on university spinouts, particularly from the 'golden triangle' of Oxford, Cambridge, and Imperial. Comparable in UK university spinout focus and EIS-eligible structure, though smaller in scale and multi-university rather than single-anchored.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oxford-science-enterprises
• Xx.com/OSI_Updates

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments190 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Science Enterprises